Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uAspire: Psilocybin in Major Depressive Disorder
NCT06308653Phase 3Active, not recruiting
- Sponsor
- Usona Institute
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of psilocybin in major depressive disorder (MDD), sponsored by Usona Institute. Started Mar 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06308653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308653.